This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
AOD-9604 (2 mg Vial)
AOD-9604 is a synthetic 16-amino-acid fragment (Tyr–hGH 177–191) studied for effects on lipolysis (fat breakdown) and lipogenesis (fat storage) without elevating IGF-1 levels or causing insulin resistance[1][2].
Quick Reference
What is AOD-9604?
Research overview based on the cited scientific literature.
• Goal: Support reduction of fat mass and enhance fat oxidation over time[1][4].
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Storage Instructions
Proper storage preserves peptide quality.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year[5].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw[6].
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is AOD-9604 studied?
AOD-9604 is a modified C-terminal fragment of human growth hormone that retains the lipolytic (fat-reducing) domain without the growth-promoting effects[1]. It binds to adipose tissue and triggers breakdown of stored fat while blocking new fat storage (re-esterification) in adipocytes[4]. At the molecular level, chronic AOD-9604 administration upregulates β3-adrenergic receptors in fat tissue, reversing obesity-related suppression of these fat-burning receptors[9]. Unlike full-length hGH, AOD-9604 does not meaningfully elevate IGF-1 levels or worsen glucose tolerance, making its tolerability indistinguishable from placebo in human trials[2][3].
What does the research report about AOD-9604?
Observations from preclinical and clinical literature.
• Supports reductions in fat mass and increases in fat oxidation over time; clinical trials showed modest but statistically significant weight loss (approximately 2.6 kg vs. 0.8 kg placebo over 12 weeks at 1 mg/day)[10].
• Preferential loss of abdominal fat observed, resembling the pattern seen with low-dose hGH therapy[10].
• Does not meaningfully raise IGF-1 and shows a placebo-like safety profile in human studies; no anti-AOD9604 antibodies detected[2][3].
• Emerging regenerative potential: preclinical studies suggest possible cartilage repair and bone health benefits[11][12].
• Generally well tolerated; occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on AOD-9604?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.